Tacrolimus extended-release - Veloxis Pharmaceuticals

Drug Profile

Tacrolimus extended-release - Veloxis Pharmaceuticals

Alternative Names: Envarsus; EnvarsusXR; LCP-Tacro™; MeltDose® tacrolimus tablets; Tacrolimus extended release; Tacrolimus-ER

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator LifeCycle Pharma
  • Developer Chiesi Farmaceutici; LifeCycle Pharma; Veloxis Pharmaceuticals
  • Class Lactones; Macrolides
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Liver transplant rejection; Renal transplant rejection
  • Discontinued Autoimmune disorders

Most Recent Events

  • 31 Mar 2017 Chiesi Farmaceutici initiates enrolment in the phase I TacroVori drug-drug interaction trial (In volunteers) in Germany (PO) (DRKS00011837)
  • 31 Mar 2017 Tacrolimus extended-release licensed to Taiba Healthcare in Middle East and North Africa
  • 01 Jan 2017 Phase-II clinical trials in Renal transplant rejection (Combination therapy) in Italy (PO) (NCT02970630)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top